PharmacoEconomics

, Volume 17, Issue 4, pp 319–324

The Importance of Achieving Additional Drug Benefits at a Reasonable Cost

A Review of the Fluoxetine Years

Authors

  • Nick Freemantle
    • Medicines Evaluation Group, Centre for Health EconomicsUniversity of York
  • James Mason
    • Medicines Evaluation Group, Centre for Health EconomicsUniversity of York
Current Opinion

DOI: 10.2165/00019053-200017040-00001

Cite this article as:
Freemantle, N. & Mason, J. Pharmacoeconomics (2000) 17: 319. doi:10.2165/00019053-200017040-00001

Abstract

Fluoxetine continues to be remarkably successful; greater volumes of this drug are sold than for any other antidepressant in the world. Prozac® has also become a household name. In this article we examine the circumstances that surround this success, and the evidence base that supports it. Rather than being a major step forward in the treatment for depression, the evidence for fluoxetine and for the selective serotonin reuptake inhibitors in general suggest at best a modest improvement in tolerability, with no evidence of improved efficacy. We note that the road to successwas not problem free for fluoxetine, and highlight the response of the sponsor in the development of subsequent drugs for CNS disorders.

Copyright information

© Adis International Limited 2000